[HTML][HTML] 甲状腺结节声像图特征与BRAFV600E基因突变的相关性研究

杨明, 罗渝昆, 张艳, 张明博, 武荣… - 中华医学超声 …, 2017 - chaosheng.cma-cmc.com.cn
… of thyroid nodules are possibly associated with BRAF V600E mutation. These signs can be
used to predict BRAF V600E mutation and facilitate subsequent treatment for such nodules. …

[PDF][PDF] 术前BRAF V600E 检测对甲状腺乳头状癌病理结局的预测价值

王敏, 张威浩, 刘俊, 杨烨, 师晓琴 - 肿瘤, 2022 - tumorsci.org
… extrathyroid extension (gETE) between the BRAF V600E mutant and BRAF V600E wild-type
patients before … Optimizing surgical treatment of papillary thyroid carcinoma associated

BRAF V600E (VE1) 在甲状腺乳头状癌中的表达及其临床意义

蔡蓉, 闵学文, 陈美蓉, 沈娅婷, 石群立, 周晓蝶 - 诊断学理论与实践, 2018 - qk.sjtu.edu.cn
… ,CK19 及Galectinr3 抗体在甲状腺乳头状癌(papillary thyroid carcinoma, PTC)中 的表达情况
,… Optimizing surgir cal treatment of papillary thyroid carcinoma associated with BRAF mutation

摄碘阳性的分化型甲状腺癌淋巴结转移灶131I 疗效分析

梅晓然, 冯方, 王辉, 韦智晓 - 中国癌症杂志, 2022 - china-oncology.com
… of 131I treatment were established, and the optimal diagnostic … in papillary thyroid cancer
with BRAF V600E mutation[J]. … for BRAF V600E mutations in papillary thyroid carcinoma[J]. …

microRNA 与甲状腺癌侵袭转移关系的研究进展

林在楷, 马保金 - 岭南现代临床外科, 2016 - lingnanwaike.com
… 发现PTC 分子标记物,例如T1799A BRAF 突变在丝裂原活化蛋白 … thyroid cancer need to be
researched in order to provide a new method for the diagno sis and treatment of thyroid cancer

[PDF][PDF] 分化型甲状腺癌初始手术治疗的争论焦点

田文 - 中国普通外科杂志, 2015 - zpwz.net
… ,并证实在已 有BRAF 6 0 0 E 突变的甲状腺乳头状癌更为常见. … Extent of surgery affects survival
for papillary thyroid cancer[J]… optimal surgical extent of the lateral neck in papillary thyroid

晚期甲状腺癌治疗的曙光——靶向和免疫治疗

刘善廷, 秦嘉黎, 范杰 - 肿瘤防治研究, 2023 - zlfzyj.com
… been approved for advanced thyroid cancer. The 2021 … treatment of advanced thyroid
cancer. This article reviews the new progress in clinical treatment of advanced thyroid carcinoma. …

[PDF][PDF] cN0 期甲状腺乳头状癌中央组淋巴结预防性清扫的研究进展

师帅, 付言涛 - 中国普通外科杂志, 2020 - zpwz.net
… the most prevalent endocrine cancer in the world, in which papillary thyroid cancer (PTC) is
… 发现BRAF 基因突变与甲状腺颈部淋巴结转移有着密切的关 系以来[29],越来越多研究发现BRAF

[PDF][PDF] 酪氨酸激酶抑制剂治疗晚期甲状腺癌的最新研究进展

何紫燕, 邱娴, 萨日, 陈立波 - 肿瘤, 2022 - tumorsci.org
Optimal timing of TKI has been equivocal. It may be … 尼的新辅助治疗策略可能改善BRAF V600E
突变的ATC 患者的预后[47] ;… or metastatic BRAF V600Mutant anaplastic thyroid cancer[J]. J …

[引用][C] 基于临床和超声特征预测甲状腺微小乳头状癌中央淋巴结转移的Nomogram

冯嘉伟, 叶晶, 胡俊, 洪礼钊, 刘胜勇, 江勇 - 重庆医科大学学报, 2022